Table 1
Outcome Measure (48 wks) | NVP 200 mg BID (n=75) | ATV/r 300/100 QD (n=77) | P value | Difference (95% CI) from model adjusting for screening VL and CD4+ |
|---|---|---|---|---|
Virologic Response (VR) | 46 (61.3%) | 50 (64.9%) | 0.71 | -4.1% (-18.3% to 10.1%) |
Virologic Failure (VF), Protocol Defined | 10 (13.3%) | 12 (15.6%) | 0.63 | -2.6% (-13.1% to 7.9%) |
Early withdrawals†| 24 | 18 |  |  |
- due to investigator-defined VF | 5 | 0 | Â | Â |
- due to adverse events | 9* | 9 | Â | Â |
- due to other reason | 10 | 9 | Â | Â |
Mean Change in TC/HDLc [baseline to week 48 (LOCF)] | -0.38 | -0.02 | 0.038 | -0.33 (-0.64 to -0.02) |